Sudden News: Director of DAEYEON Group Passes Away Unexpectedly Amid IPO Filing
Xian Janssen
Pharmaceutical R&D and Manufacturer
Livzon
Pharmaceutical R&D, Manufacturing, and Sales Enterprises
Source: Every Day Economic News
Yuanhe Pharmaceutical Group Lndustry Co.,ltd. Announced on December 2 that Mr. Guan Ping, a director of the company, unfortunately passed away due to an accident on December 1, 2025.
Yuanhe Pharmaceutical Group Lndustry Co.,ltd. expressed that the directors, supervisors, senior management, and all employees of the company pay the highest respect and heartfelt thanks to Mr. Guan Ping for his hard work and outstanding contributions during his tenure. We deeply mourn and remember Mr. Guan Ping’s passing and extend our sincere condolences to his family.
According to the 2025 semi-annual report of Yuanhe Pharmaceutical Group Lndustry Co.,ltd., Guan Ping was born in October 1961.Holding 500,000 shares of the company's stock, accounting for 0.81% of the company's total share capital.
Public information shows that Guan Ping is a senior professional manager in China's pharmaceuticals industry. He has won awards such as one of the Top Ten Professional Managers in China and one of the Top Ten Pharmaceutical Elites. He is regarded as a teacher and elder brother by many professional managers, and many people respectfully call him "Brother Guan."He has worked in pharmaceutical companies such as Xian Janssen, Livzon Pharmaceutical Group, Wyeth Pharmaceuticals, Shijiazhuang Pharmaceutical Group, and Dongsheng Technology.
According to The Paper's report, during the nascent period of China's pharmaceutical market,Guan Ping once managed blockbuster products worth hundreds of millions, such as Caltrate and White Plus Black, earning him the titleOTC"Prince of (Over-the-Counter Drugs)""The title 'Lord Guan' is associated with seniority, age, adherence to rules, dignity in conduct, and also carries a sense of self-respect and freedom," said a close friend of Guan Ping in the industry while paying tribute to him in a video.
Guan Ping once recounted, "After graduating from Xi'an University of Technology in 1983, I stayed at the university to become a teacher. At that time, the trend of venturing into business was gradually rising. After some internal struggle, I resigned from my 'secure job' in 1988.Join Xian Janssen and become the second local pharmaceutical representative of this joint venture.
A major turning point in his career came in 1997 when he joined Wyeth-Baiwang Company as the Regional Marketing Director.The sentence that deeply moved Guan Ping from P.K, the foreign general manager, was: "By entering our company, you are standing at the forefront of the trend." At that time, the company's main product, Caltrate D, had been removed from the list of publicly funded medicines, and thus shifted from the hospital market to the OTC retail market. The latter was still an untapped frontier for pharmaceutical companies.
The transition to OTC was also a huge change for Guan Ping, but he enjoyed the "feeling of being at the forefront." He and the marketing department planned many activities—display competitions in pharmacies, training sessions for pharmacy staff, and preparing gifts on-site. After half an hour of training, they would ask the staff questions, and those who answered correctly received rewards. At that time, no pharmaceutical company had done this in the retail market; the atmosphere on-site was lively, and the results were good.
In 1998, the sales of Caltrate D increased by nearly 20% instead of declining, and its retail market share far exceeded that of hospitals.
In 2001, Guan Ping joined Dongsheng Technology as a director and vice president. At that time, the state required the discontinuation of pharmaceutical preparations containing PPA (phenylpropanolamine), and Contac, the leading brand of cold medicine in China from Sino-American SmithKline, fell accordingly. Dongsheng Technology, which had just taken over the brand "White and Black," launched an aggressive advertising campaign emphasizing that "White and Black" was "PPA-free," while also pushing hard in retail pharmacies.Guan Ping proposed the "24 Tasks for OTC Representatives Entering Stores," enabling a large number of salespeople to engage in promotional activities and product displays at retail outlets.
Thereafter, the sales of Baijiahei soared from more than 20 million to over 200 million yuan. The senior marketing team of Dongsheng creatively built the "Dongsheng" brand through Baijiahei, and then launched the "Dongsheng Anti-Cold Family" under the "Dongsheng" brand, thereby driving the sales of other secondary products.
It is worth mentioning that the profit source of pharmaceutical distributors at that time was the difference between purchase and sales prices. Guan Ping noticed that as a large number of pharmaceutical distributors flooded into the market, their profits continued to shrink. In order to engage in price wars at the terminal end, the wholesale price had even been lower than the factory price, resulting in negative profits.In 2002, Dongsheng was the first in the industry to adopt an agency commission system, attempting to allow distributors to profit from sales volume rather than the price difference of individual products, thereby working with distributors to expand the market.
By 2004, the sales of Dongsheng Anti-Cold Family broke through 50 million yuan, and Baijiahei even set a record of 500 million yuan.